Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication

키워드

참고문헌 (139)

1. Hajarizadeh B, "Epidemiology and natural history of HCV infection", Nat Rev Gastroenterol Hepatol, 10, pp.553~562 (2013)
2. Yang JD, "A global view of hepatocellular carcinoma : trends, risk, prevention and management", Nat Rev Gastroenterol Hepatol, 16, pp.589~604 (2019)
3. Cui F, "Global reporting of progress towards elimination of hepatitis B and hepatitis C", Lancet Gastroenterol Hepatol, 8, pp.332~342 (2023)
4. Morgan RL, "Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma : a meta-analysis of observational studies", Ann Intern Med, 158(5 Pt 1), pp.329~337 (2013)
5. Ioannou GN, "HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma", J Hepatol, 68, pp.25~32 (2018)
6. Kanda T, "APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation", Hepatol Int, 13, pp.649~661 (2019)
7. Waziry R, "Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy : a systematic review, meta-analyses, and meta-regression", J Hepatol, 67, pp.1204~1212 (2017)
8. Seko Y, "Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents", J Gastroenterol, 57, pp.90~98 (2022)
9. Sarasin FP, "Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis", Am J Med, 101, pp.422~434 (1996)
10. Farhang Zangneh H, "Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis", Clin Gastroenterol Hepatol, 17, pp.1840~1849 (2019)
11. Parikh ND, "Costeffectiveness of hepatocellular carcinoma surveillance : an assessment of benefits and harms", Am J Gastroenterol, 115, pp.1642~1649 (2020)
12. European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C : final update of the series", J Hepatol, 73, pp.1170~1218 (2020)
13. "HCV guidance: recommendations for testing, managing, and treating hepatitis C"[URL]
14. Singal AG, "AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma", Hepatology, 78, pp.1922~1965 (2023)
15. Yu ML, "2020 Taiwan consensus statement on the management of hepatitis C : part(I)general population", J Formos Med Assoc, 119, pp.1019~1040 (2020)
16. Huang CF, "Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals", Hepatol Int, 12, pp.544~551 (2018)
17. Kim NJ, "Fibrosis stage-specific incidence of hepatocellular cancer after hepatitis C cure with direct-acting antivirals : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 21, pp.1723~1738 (2023)
18. D’Ambrosio R, "Hepatocellular carcinoma risk, outcomes, and screening after hepatitis C eradication", Hepatol Commun, 5, pp.1465~1468 (2021)
19. Nakatsuka T, "Development and prognosis of hepatocellular carcinoma in patients with diabetes", Clin Mol Hepatol, 29, pp.51~64 (2023)
20. Huang CF, "Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy", Medicine(Baltimore), 95, pp.e4157~ (2016)
21. Pelusi S, "Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals", Liver Int, 43, pp.1593~1603 (2023)
22. Tokuchi Y, "Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight", Hepatol Res, 53, pp.595~606 (2023)
23. Fouad Y, "MAFLD considerations as a part of the global hepatitis C elimination effort : an international perspective", Aliment Pharmacol Ther, 53, pp.1080~1089 (2021)
24. Ji D, "Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients : a prospective fouryears follow-up study", Metabol Open, 10, pp.100090~ (2021)
25. Peleg N, "Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response", J Viral Hepat, 26, pp.1257~1265 (2019)
26. Mueller PP, "Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication", J Hepatol, 77, pp.55~62 (2022)
27. Ioannou GN, "Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores", Gastroenterology, 157, pp.1264~1278 (2019)
28. Yu ML, "Time-degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatitis C Virus patients : a model for prioritization of treatment", Clin Cancer Res, 23, pp.1690~1697 (2017)
29. Huang CF, "Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in noncirrhotic patients with successful hepatitis C virus eradication", J Hepatol, 61, pp.67~74 (2014)
30. Yu ML, "A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy", Hepatology, 44, pp.1086~1097 (2006)
31. Asahina Y, "α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C", Hepatology, 58, pp.1253~1262 (2013)
32. Tanaka Y, "HCC risk post-SVR with DAAs in East Asians : findings from the REAL-C cohort", Hepatol Int, 14, pp.1023~1033 (2020)
33. Ioannou GN, "Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C", J Hepatol, 69, pp.1088~1098 (2018)
34. Alonso López S, "A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis", Hepatology, 72, pp.1924~1934 (2020)
35. Semmler G, "HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease", J Hepatol, 76, pp.812~821 (2022)
36. Ioannou GN, "Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis", JAMA Netw Open, 3, pp.e2015626~ (2020)
37. Lu MY, "Decision tree algorithm predicts hepatocellular carcinoma among chronic hepatitis C patients following viral eradication", Am J Cancer Res, 13, pp.190~203 (2023)
38. Reig M, "Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy", J Hepatol, 65, pp.719~726 (2016)
39. Singal AG, "Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study", Gastroenterology, 156, pp.1683~1692 (2019)
40. Saraiya N, "Systematic review with meta-analysis : recurrence of hepatocellular carcinoma following direct-acting antiviral therapy", Aliment Pharmacol Ther, 48, pp.127~137 (2018)
41. Sapena V, "Hepatocellular carcinoma recurrence after direct-acting antiviral therapy : an individual patient data meta-analysis", Gut, 71, pp.593~604 (2022)
42. Fujimoto A, "Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer", Nat Genet, 48, pp.500~509 (2016)
43. Fujimoto A, "Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators", Nat Genet, 44, pp.760~764 (2012)
44. Schulze K, "Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets", Nat Genet, 47, pp.505~511 (2015)
45. Totoki Y, "High-resolution characterization of a hepatocellular carcinoma genome", Nat Genet, 43, pp.464~469 (2011)
46. Totoki Y, "Trans-ancestry mutational landscape of hepatocellular carcinoma genomes", Nat Genet, 46, pp.1267~1273 (2014)
47. The Cancer Genome Atlas Research Network, "Comprehensive and integrative genomic characterization of hepatocellular carcinoma", Cell, 169, pp.1327~1341 (2017)
48. Imamura T, "Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation", Cancer Med, 11, pp.1769~1786 (2022)
49. Rebouissou S, "Advances in molecular classification and precision oncology in hepatocellular carcinoma", J Hepatol, 72, pp.215~229 (2020)
50. Fine B, "Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a", Science, 325, pp.1261~1265 (2009)
51. Shibata T, "Exploration of liver cancer genomes", Nat Rev Gastroenterol Hepatol, 11, pp.340~349 (2014)
52. Kumar V, "Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma", Nat Genet, 43, pp.455~458 (2011)
53. Bauer S, "Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA", Science, 285, pp.727~729 (1999)
54. Lee MH, "Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes : a genome-wide association study", Hepatology, 67, pp.651~661 (2018)
55. Matsuura K, "Genome-wide association study identifies TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus infection", Gastroenterology, 152, pp.1383~1394 (2017)
56. Degasperi E, "Hepatic fat-genetic risk score predicts hepatocellular carcinoma in patients with cirrhotic HCV treated with DAAs", Hepatology, 72, pp.1912~1923 (2020)
57. Chang KC, "A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection", Clin Gastroenterol Hepatol, 13, pp.1017~1024 (2015)
58. Sharma S, "Epigenetics in cancer", Carcinogenesis, 31, pp.27~36 (2010)
59. Estel ler M, "Epigenet ics in cancer", N Engl J Med, 358, pp.1148~1159 (2008)
60. Rothbart SB, "Interpreting the language of histone and DNA modifications", Biochim Biophys Acta, 1839, pp.627~643 (2014)
61. Conte M, "Molecular pathways : the complexity of the epigenome in cancer and recent clinical advances", Clin Cancer Res, 18, pp.5526~5534 (2012)
62. Balasubramanyam K, "Small molecule modulators of histone acetyltransferase p300", J Biol Chem, 278, pp.19134~19140 (2003)
63. Perez S, "Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals", PLoS Genet, 15, pp.e1008181~ (2019)
64. Hamdane N, "HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response", Gastroenterology, 156, pp.2313~2329 (2019)
65. Jühling F, "Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma", Gut, 70, pp.157~169 (2021)
66. Hlady RA, "Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance", Hepatology, 75, pp.983~996 (2022)
67. Sugimachi K, "Persistent epigenetic alterations in transcription factors after a sustained virological response in hepatocellular carcinoma", JGH Open, 6, pp.854~863 (2022)
68. Nagata H, "Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C", J Hepatol, 67, pp.933~939 (2017)
69. Nahon P, "Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs", Gastroenterology, 155, pp.1436~1450 (2018)
70. Janjua NZ, "The impact of SVR from direct-acting antiviral-and interferon-based treatments for HCV on hepatocellular carcinoma risk", J Viral Hepat, 27, pp.781~793 (2020)
71. Celsa C, "Direct-acting antiviral agents and risk of Hepatocellular carcinoma : critical appraisal of the evidence", Ann Hepatol, 27(Suppl 1), pp.100568~ (2022)
72. Alao H, "Baseline intrahepatic and peripheral innate immunity are associated with hepatitis C virus clearance during directacting antiviral therapy", Hepatology, 68, pp.2078~2088 (2018)
73. Amaddeo G, "Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy", Liver Int, 40, pp.74~82 (2020)
74. Holmes JA, "Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection", J Viral Hepat, 26, pp.362~372 (2019)
75. Sung PS, "Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling", Clin Mol Hepatol, 24, pp.302~310 (2018)
76. Hengst J, "Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C", J Infect Dis, 214, pp.1965~1974 (2016)
77. Khera T, "Long-lasting imprint in the soluble inflammatory milieu despite early treatment of acute symptomatic hepatitis C", J Infect Dis, 226, pp.441~452 (2022)
78. Rosenberg BR, "Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance", PLoS Pathog, 14, pp.e1007290~ (2018)
79. Lunemann S, "NK cells in hepatitis C : role in disease susceptibility and therapy", Dig Dis, 30(Suppl 1), pp.48~54 (2012)
80. Lunemann S, "Compromised function of natural killer cells in acute and chronic viral hepatitis", J Infect Dis, 209, pp.1362~1373 (2014)
81. Golden-Mason L, "Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure", Gut, 57, pp.1121~1128 (2008)
82. Serti E, "Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function", Gastroenterology, 149, pp.190~200 (2015)
83. Golden-Mason L, "Early and late changes in natural killer cells in response to ledipasvir", sofosbuvir treatment, 2018, pp.2, 364~375
84. Jiang HJ, "Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients", Clin Exp Med, 19, pp.299~308 (2019)
85. Strunz B, "Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity", Nat Commun, 9, pp.2275~ (2018)
86. Werner JM, "Immune reconstitution after HCV clearance with direct antiviral agents : potential consequences for patients with HCC?", Transplantation, 101, pp.904~909 (2017)
87. Chu PS, "On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C", PLoS One, 12, pp.e0179096~ (2017)
88. Rosen HR, "Control of HCV infection by natural killer cells and macrophages", Cold Spring Harb Perspect Med, 10, pp.a037101~ (2020)
89. Ghosh A, "Persistent gamma delta T-cell dysfunction in chronic HCV infection despite direct-acting antiviral therapy induced cure", J Viral Hepat, 26, pp.1105~1116 (2019)
90. Hengst J, "Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy", Eur J Immunol, 46, pp.2204~2210 (2016)
91. Bolte FJ, "Intra-hepatic depletion of mucosal-associated invariant T cells in hepatitis C virus-induced liver inflammation", Gastroenterology, 153, pp.1392~1403 (2017)
92. Khlaiphuengsin A, "Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection", PLoS One, 15, pp.e0244112~ (2020)
93. Niehaus CE, "MAIT cells are enriched and highly functional in ascites of patients with decompensated liver cirrhosis", Hepatology, 72, pp.1378~1393 (2020)
94. Mehta H, "MAIT cells in liver inflammation and fibrosis", Semin Immunopathol, 44, pp.429~444 (2022)
95. Heim MH, "Innate and adaptive immune responses in HCV infections", J Hepatol, 61(1 Suppl), pp.S14~S25 (2014)
96. Aregay A, "Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses", J Hepatol, 71, pp.889~899 (2019)
97. Tonnerre P, "Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory", Nat Immunol, 22, pp.1030~1041 (2021)
98. Llorens-Revull M, "Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy", PLoS One, 16, pp.e0254243~ (2021)
99. Shin EC, "Immune responses and immunopathology in acute and chronic viral hepatitis", Nat Rev Immunol, 16, pp.509~523 (2016)
100. Hensel N, "Memory-like HCV-specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection", Nat Immunol, 22, pp.229~239 (2021)
101. Yates KB, "Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans", Nat Immunol, 22, pp.1020~1029 (2021)
102. Alfei F, "TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection", Nature, 571, pp.265~269 (2019)
103. Doedens AL, "Hypoxia-inducible factors enhance the effector responses of CD8(+)T cells to persistent antigen", Nat Immunol, 14, pp.1173~1182 (2013)
104. Oltmanns C, "Reverse inflammaging : long-term effects of HCV cure on biological age", J Hepatol, 78, pp.90~98 (2023)
105. Hartnell F, "Characterizing hepatitis C virus-specific CD4+ T cells following viral-vectored vaccination, directly acting antivirals, and spontaneous viral cure", Hepatology, 72, pp.1541~1555 (2020)
106. Ghosh A, "Lymphocyte landscape after chronic hepatitis C virus(HCV)cure : the new normal", Int J Mol Sci, 21, pp.7473~ (2020)
107. Langhans B, "Increased peripheral CD4+ regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C", J Hepatol, 66, pp.888~896 (2017)
108. Fu J, "Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients", Gastroenterology, 132, pp.2328~2339 (2007)
109. Telatin V, "In chronic hepatitis C infection, myeloid-derived suppressor cell accumulation and T cell dysfunctions revert partially and late after successful direct-acting antiviral treatment", Front Cell Infect Microbiol, 9, pp.190~ (2019)
110. Lu MY, "Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication", World J Gastroenterol, 28, pp.140~153 (2022)
111. Debes JD, "Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals", Gastroenterology, 154, pp.515~517 (2018)
112. Owusu Sekyere S, "Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients", United European Gastroenterol J, 9, pp.486~496 (2021)
113. Macek Jílková Z, "Circulating IL-13 is associated with de novo development of HCC in HCV-infected patients responding to direct-acting antivirals", Cancers(Basel), 12, pp.3820~ (2020)
114. Watanabe T, "AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy", BMC Cancer, 21, pp.699~ (2021)
115. Yoshimasu Y, "Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C", J Gastrointestin Liver Dis, 28, pp.63~71 (2019)
116. Yasui Y, "Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus", Hepatol Res, 48, pp.1131~1139 (2018)
117. Biselli M, "A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis", Br J Cancer, 112, pp.69~76 (2015)
118. Mücke VT, "Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response", Liver Int, 39, pp.2174~2183 (2019)
119. Faillaci F, "Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals", Hepatology, 68, pp.1010~1024 (2018)
120. Ramadan HK, "Correlation between vascular endothelial growth factor and long-term occurrence of HCVrelated hepatocellular carcinoma after treatment with directacting antivirals", Cancer Invest, 39, pp.653~660 (2021)
121. Huang CF, "Genetics variants and serum levels of MHC class I chain-related A in predicting hepatocellular carcinoma development in chronic hepatitis C patients post antiviral treatment", EBioMedicine, 15, pp.81~89 (2017)
122. Huang CF, "Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication", J Gastroenterol Hepatol, 34, pp.249~255 (2019)
123. Pascut D, "Serum miRNA are promising biomarkers for the detection of early hepatocellular carcinoma after treatment with direct-acting antivirals", Cancers(Basel), 11, pp.1773~ (2019)
124. Tsai YS, "Circulating Let-7 family members as non-invasive biomarkers for predicting hepatocellular carcinoma risk after antiviral treatment among chronic hepatitis C patients", Cancers(Basel), 14, pp.2023~ (2022)
125. Nakagawa S, "Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition", Cancer Cell, 30, pp.879~890 (2016)
126. Liang D, "Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease", Biochim Biophys Acta Mol Basis Dis, 1864, pp.133~142 (2018)
127. Lupberger J, "EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy", Nat Med, 17, pp.589~595 (2011)
128. Ninio L, "Hepatitis C virus enhances the invasiveness of hepatocellular carcinoma via EGFR-mediated invadopodia formation and activation", Cells, 8, pp.1395~ (2019)
129. Marti-Aguado D, "Cigarette smoking and liver diseases", J Hepatol, 77, pp.191~205 (2022)
130. Valenti L, "Dysmetabolism, diabetes and clinical outcomes in patients cured of chronic hepatitis C : a real-life cohort study", Hepatol Commun, 6, pp.867~877 (2022)
131. Tsai PC, "Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan", J Hepatol, 78, pp.281~292 (2023)
132. Zeng RW, "Meta-analysis : chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin", Aliment Pharmacol Ther, 57, pp.600~609 (2023)
133. Goh MJ, "Statin and aspirin for chemoprevention of hepatocellular carcinoma : time to use or wait further?", Clin Mol Hepatol, 28, pp.380~395 (2022)
134. Ji F, "Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma : a systematic review and meta-analysis", J Hepatol, 71, pp.473~485 (2019)
135. Cheng PN, "Sofosbuvir", velpatasvir for hepatitis C virus infection : realworld effectiveness and safety from a nationwide registry in Taiwan, 2022, pp.11, 485~500
136. Huang CF, "Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan", Sci Rep, 11, pp.23473~ (2021)
137. Yeh ML, "Characteristics and survival outcomes of hepatocellular carcinoma developed after HCV SVR", Cancers(Basel), 13, pp.3455~ (2021)
138. Toyoda H, "Characteristics and prognosis of de novo hepatocellular carcinoma after sustained virologic response", hepatol commun, 5, pp.1290~1299 (2021)
139. Jongraksak T, "Outcomes of direct-acting antivirals in patients with HCV decompensated cirrhosis : a systematic review and meta-analysis", Front Med(Lausanne), 10, pp.1295857~ (2023)

관련 논문AI추천